Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?

To: Aggie who wrote (723)	3/11/2000 12:32:00 PM
From: JDN	Read Replies (1) \| Respond to of 783

Dear Aggie: Had I understood the mechanics of how BCHE was marketing their drugs when I bought this stock nearly 2 years ago I never would have. They are as follows: Glaxo handles the marketing/distribution of the successful drugs you are aware of with BCHE. The good part is Glaxo paid them plenty for this right and took over a potential big expense load thus BCHE actually is one of the few who actually make money and have a pretty sound financial condition. The bad news, is that limited forever BCHE's profit potential on THOSE drugs. Now however, BCHE had changed their approach on NEW DRUGS. They are setting up their own marketing and distribution channels and will market alone and keep all the profits to themselves. Because the are now financially sound they should be able to accomplish this. Now, the question is WILL they have outstanding drugs to market. If you believe that they will then it would be foolish for you to sell your BCHE stock after 5 years as in the next year or two BCHE should be performing like the others, maybe even better. If you believe they will have a dry hole then yes its time to leave. JDN